Lipid-based amphotericin B: A review of the last 10 years of use

International Journal of Antimicrobial Agents

Volumn 17, Issue 3, 2001, Pages 161-169

  Hann, Ian M ^a   Prentice, H Grant ^b  

^a GREAT ORMOND STREET HOSPITAL   (United Kingdom)

^b ROYAL FREE HOSPITAL   (United Kingdom)

Author keywords

Fungi; Liposomal amphotericin; Neutropenia

Indexed keywords

AMPHOTERICIN B; AMPHOTERICIN B CHOLESTEROL SULFATE; AMPHOTERICIN B LIPID COMPLEX; ECHINOCANDIN B; ITRACONAZOLE; POSACONAZOLE;

ANTIBIOTIC PROPHYLAXIS; ANTIFUNGAL ACTIVITY; DRUG DEVELOPMENT; DRUG USE; FEBRILE NEUTROPENIA; HUMAN; MORTALITY; MYCOSIS; NEPHROTOXICITY; PREMEDICATION; PRIORITY JOURNAL; REVIEW; RISK;

AMPHOTERICIN B; ANTIBIOTICS, ANTIFUNGAL; CLINICAL TRIALS; COSTS AND COST ANALYSIS; HEMATOLOGIC DISEASES; HUMANS; MYCOSES; NEOPLASMS; NEUTROPENIA; RANDOMIZED CONTROLLED TRIALS;

EID: 0035105654     PISSN: 09248579     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0924-8579(00)00341-1     Document Type: Review

References (50)

1. Diagnosis and prevention of fungal infection in the immunocompromised patient
2. Treatment-related deaths during induction and first remission of acute myeloid leukaemia in children treated on the MRC AML 10 trial
3. Aspergillosis after high dose chemotherapy and autologous stem cell transplantation
4. A controlled trial of fluconazole to prevent fungal infections in patients undergoing bone marrow transplantation
5. Clinical features and analysis of risk factors for invasive candida infection after marrow transplantation
6. Fungal infections in hematological malignancies: Advances in laboratory diagnosis and therapy
7. Progress in the diagnosis and management of aspergillosis in bone marrow transplantation: 13 years experience
8. Infectious complications in 126 patients treated with high dose chemotherapy and autologous peripheral blood stem cell transplantation
9. Surveillance tests for the diagnosis of fungal infections in bone marrow transplant recipients
10. Candida infections in bone marrow transplant recipients
11. Fluconazole prophylaxis of fungal infections in patients with acute leukaemia - results of a randomised placebo-controlled, double-blind multicentre trial
12. Empiric antibiotic and antifungal therapy for cancer patients with prolonged fever and granulocytopenia
13. Empiric antifungal therapy in febrile granulocytopenic patients
14. Fluconazole versus amphotericin B as empirical antifungal therapy of unexplained fever in granulocytopenic cancer patients
15. A randomised trial comparing fluconazole with amphotericin B for the treatment of candidemia in patients without neutropenia
16. Antifungal agents. Part II: The azoles
17. A controlled trial of the tolerance of amphotericin B infused in dextrose or in intralipid in patients with haematological malignancies
18. Reduced renal toxicity and improved clinical tolerance of amphotericin B mixed with intralipid compared with conventional amphotericin B in neutropenic patients
19. Admimstration of lipid-emulsion versus conventional amphotericin B in patients with neutropenia
20. Safety and toxicity of amphotericin B in glucose 5% or intralipid 20% in neutropenic patients with pneumonia or fever of unknown origin: randomised study
21. Liposomal amphotericin B in the treatment of fungal infections in neutropenic patients: a single centre experience of 133 episodes in 116 patients
22. Liposomal amphotericin B (Ambisome): Safety data from a phase II/III clinical trial
23. Efficacy of amphotericin F encapsulated in liposomes (Ambisome) in the treatment of invasive fungal infections in immunocompromised patients
24. Liposomal amphotericin B (ambisome) in children with febrile neutropenia and renal dysfunction
25. Fungemia in the immunocompromised host. Changing patterns, antigenaemia, high mortality
26. Amphotericin B lipid complex (ABLC) for invasive fungal infections: Analysis of safety and efficacy in 556 cases
27. Amphotericin colloidal dispersion vs Amphotericin B as therapy for invasive aspergillosis
28. A randomised comparison of liposomal versus conventional amphotericin for the treatment of pyrexia of unknown origin in neutropenic patients
29. Liposomal amphotericin B for empirical therapy in patients with persistent fever and neutropenia
30. Enhanced phagocytosis and intra-cellular killing of candida albicans by GM-CSF activated neutrophils
31. Antifungal activity against aspergillus fumigatus hyphae-enhanced by GM-CSF
32. Randomised, double-blind clinical trial of amphotericin B colloidal dispersion (ABCD) versus amphotericin B in the empirical treatment of fever and neutropenia
33. An EORTC international multicentre randomised trial comparing two dosages of liposomal amphotericin B for treatment of invasive aspergillosis
34. Liposomal amphotericin B deoxycholate in the treatment of documented and suspected neutropenic associated invasive infections
35. Amphotericin B colloidal dispersion (Amphocil) versus fluconazole for the prevention of fungal infections in neutropenic patients: data of a prematurely stopped trial
36. Randomised double-blind study of liposomal amphotericin B (ambisome) prophylaxis of invasive fungal infections in bone marrow transplant recipients
37. Liposomal aniphotericia (ambisome) in the prophylaxis of fungal infections in neutropenic patients: a randomised, double-blind, placebo-controlled study
38. Clinical significance of nephrotoxicity in patients treated with amphotericin B for suspected or proven aspergillosis
39. Late effects of intensive treatment for acute myeloid leukaemia and myelodysplasia in childhood
40. Emerging applications of recombinant human granulocyte-macrophage colony-stimulating factor
41. Antifungal therapy in bone marrow failure
42. Diagnosis of invasive aspergillosis in bone marrow transplant recipients by polymerase chain reaction
43. Comparison of antigen detection and PCR assay for invasive pulmonary aspergillosis
44. Diagnosis and prevention of fungal infections in the immunocompromised patient.